Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6818990 | 0.83 | DRD2 (0.42) | CRHR1POLBLMNATP53L3MBTL1 | |
| SCHEMBL2686133 | 0.76 | CRHR1 (0.39) | CRHR1GAACNR2TGFBR1 | |
| SCHEMBL12506456 | 0.76 | LMNA (0.48) | POLBTSHRLMNATP53L3MBTL1 | |
| SCHEMBL3628802 | 0.75 | POLB (0.42) | POLBTSHRLMNATP53L3MBTL1 | |
| SCHEMBL14658671 | 0.74 | TRPV1 (0.42) | CRHR1TGFBR1 | |
| SCHEMBL12506474 | 0.74 | TRPV1 (0.44) | POLBTSHRTGFBR1 | |
| SCHEMBL2688159 | 0.74 | TRPV1 (0.50) | CRHR1 | |
| SCHEMBL21780683 | 0.73 | CRHR1 (0.57) | CRHR1POLBTSHRLMNAGAA | |
| SCHEMBL2684760 | 0.73 | TRPV1 (0.46) | — | |
| SCHEMBL24758363 | 0.72 | GAA (0.44) | CRHR1GAACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638015-A1 | SUBSTITUTED BICYCLIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2013-09-18 | — | — | EP | disclosed |
| EP-2638034-A1 | SUBSTITUTED HETEROAROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062463-A1 | SUBSTITUTED BICYCLIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062462-A1 | SUBSTITUTED HETEROAROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2012-05-18 | — | — | WO | disclosed |
| US-20120115903-A1 | Substituted Heteroaromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20120115893-A1 | Substituted Bicyclic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115903-A1 | Substituted Heteroaromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | TRPV1, OPRM1, OPRK1 | CRHR1 101/4885POLB 4344/4885TSHR 1352/4885 |
| US-20120115893-A1 | Substituted Bicyclic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | TRPV1, CNR1, CNR2 | CRHR1 115/4885POLB 4082/4885TSHR 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.